Document Detail

Vitamin D biology in heart failure: molecular mechanisms and systematic review.
MedLine Citation:
PMID:  20795939     Owner:  NLM     Status:  In-Process    
Vitamin D has recently been suggested as an important mediator of blood pressure and cardiovascular disease, including heart failure. In patient with heart failure, low vitamin D levels are associated with adverse outcome and correlate with established clinical correlates and biomarkers. Many precursor states of heart failure, such as hypertension, atherosclerosis, and diabetes are more prevalent in subjects with low vitamin D levels. Recent experimental data have provided clues how vitamin D might exert cardioprotective effects. The steroid hormone vitamin D regulates gene expression of many genes that play a prominent role in the progression of heart failure, such as cytokines and hormones. Specifically, vitamin D is a negative regulator of the hormone renin, the pivotal hormone of the renin-angiotensin system. Mechanistic insights were gained by studying mice deficient for the vitamin D receptor, which develop hypertension and adverse cardiac remodeling mediated via the renin-angiotensin system. Furthermore, vitamin D receptor is expressed in the heart and regulated under pro-hypertrophic stimuli and vitamin D as receptor has been associated with the expression of other hypertrophic genes such as natriuretic peptides. So, epidemiological data and mechanistic studies have provided strong support for a potentially cardioprotective effect of vitamin D. It remains unclear if vitamin D supplementation is beneficial in preventing heart failure or if it could be a therapeutic addendum in the treatment of heart failure. This review summarizes current knowledge on vitamin D and its biology in heart failure.
Laura M G Meems; P van der Harst; W H van Gilst; R A de Boer
Related Documents :
19357309 - Experimentally observed phenomena on cardiac energetics in heart failure emerge from si...
19168509 - Inflammation as a therapeutic target in heart failure? a scientific statement from the ...
19147689 - Minimizing cardiotoxicity while optimizing treatment efficacy with trastuzumab: review ...
2152859 - Digitalis: a drug that refuses to die.
11206099 - Left ventricular dysfunction and cytoprotection.
17149679 - What is evidence-based, what is new in medical therapy of acute heart failure?
10151039 - Intracoronary stents: a review of the experience with five different devices in clinica...
23826739 - Evaluation of left ventricular systolic function revisited in septic shock.
9649929 - Warfarin reduces silent cerebral infarction in elderly patients with atrial fibrillation.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Current drug targets     Volume:  12     ISSN:  1873-5592     ISO Abbreviation:  Curr Drug Targets     Publication Date:  2011 Jan 
Date Detail:
Created Date:  2010-12-06     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100960531     Medline TA:  Curr Drug Targets     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  29-41     Citation Subset:  IM    
Department of Cardiology, University Medical Center Groningen, University of Groningen, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Vitamin D in chronic kidney disease: new potential for intervention.
Next Document:  Accuracy of 25-hydroxyvitamin D assays: confronting the issues.